Jorey Chernett Purchases 18,000 Shares of Oncology Institute (NASDAQ:TOI) Stock

Posted by Francis Steltz on Jun 24th, 2026

The Oncology Institute, Inc. (NASDAQ:TOI – Get Free Report) major shareholder Jorey Chernett purchased 18,000 shares of the company’s stock in a transaction dated Tuesday, June 23rd. The stock was bought at an average cost of $5.02 per share, for a total transaction of $90,360.00. Following the completion of the purchase, the insider directly owned 10,615,858 shares of the company’s stock, valued at $53,291,607.16. The trade was a 0.17% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Jorey Chernett also recently made the following trade(s):

On Thursday, June 4th, Jorey Chernett acquired 12,000 shares of Oncology Institute stock. The shares were purchased at an average cost of $4.75 per share, with a total value of $57,000.00.
On Wednesday, May 20th, Jorey Chernett bought 33,500 shares of Oncology Institute stock. The stock was purchased at an average price of $4.07 per share, for a total transaction of $136,345.00.
On Tuesday, May 19th, Jorey Chernett bought 5,000 shares of Oncology Institute stock. The stock was purchased at an average cost of $4.05 per share, for a total transaction of $20,250.00.
On Tuesday, May 19th, Jorey Chernett purchased 30,000 shares of Oncology Institute stock. The shares were purchased at an average cost of $4.09 per share, with a total value of $122,700.00.
On Thursday, April 9th, Jorey Chernett purchased 20,000 shares of Oncology Institute stock. The shares were purchased at an average price of $3.10 per share, with a total value of $62,000.00.

Oncology Institute Stock Performance

Shares of NASDAQ TOI traded up $0.21 during trading hours on Wednesday, hitting $5.25. The stock had a trading volume of 454,195 shares, compared to its average volume of 1,871,028. The firm’s 50-day moving average price is $4.27 and its two-hundred day moving average price is $3.56. The Oncology Institute, Inc. has a 52 week low of $2.02 and a 52 week high of $5.57. The company has a market capitalization of $518.41 million, a P/E ratio of -14.20 and a beta of 0.37.

Oncology Institute (NASDAQ:TOI – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.05. The business had revenue of $147.44 million for the quarter, compared to the consensus estimate of $142.10 million. As a group, analysts expect that The Oncology Institute, Inc. will post -0.17 EPS for the current fiscal year.

Analysts Set New Price Targets

TOI has been the subject of several analyst reports. B. Riley Financial lifted their price objective on shares of Oncology Institute from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Needham & Company LLC upped their price target on Oncology Institute from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oncology Institute in a report on Monday, April 20th. Finally, BTIG Research raised their price objective on Oncology Institute from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, June 8th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.75.

View Our Latest Research Report on TOI

Hedge Funds Weigh In On Oncology Institute

Institutional investors have recently made changes to their positions in the business. Josh Arnold Investment Consultant LLC lifted its holdings in shares of Oncology Institute by 1,104.3% during the fourth quarter. Josh Arnold Investment Consultant LLC now owns 2,459,809 shares of the company’s stock worth $8,757,000 after buying an additional 2,255,559 shares during the last quarter. Kanen Wealth Management LLC acquired a new stake in shares of Oncology Institute in the third quarter worth $6,421,000. Marshall Wace LLP acquired a new stake in shares of Oncology Institute in the second quarter worth $3,028,000. Geode Capital Management LLC increased its position in Oncology Institute by 231.7% during the second quarter. Geode Capital Management LLC now owns 1,279,443 shares of the company’s stock worth $2,623,000 after acquiring an additional 893,696 shares during the period. Finally, UBS Group AG raised its stake in Oncology Institute by 151.2% during the 3rd quarter. UBS Group AG now owns 1,055,862 shares of the company’s stock valued at $3,685,000 after purchasing an additional 635,489 shares during the last quarter. 36.86% of the stock is currently owned by institutional investors.

About Oncology Institute

(Get Free Report)

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.